New Study Data Confirms NLS Pharmaceutics' Mazindol Orexin Pathway Activation For Sleeping Disorder

• NLS Pharmaceutics Ltd (NASDAQ: NLSP) has announced new study data which support the mechanism of action for mazindol, the active compound in the Company's lead product candidate to treat narcolepsy, Quilience.

• Narcolepsy is a chronic sleep disorder caused by a deficiency in orexin, a neuropeptide that regulates the sleep-wake cycle.

• The new data confirm mazindol's Orexin-2 receptor (OX2R) agonist activity.

• In the pre-clinical study conducted by the Department of Biomedical Sciences at the University of Lausanne and sponsored by NLS, mice genetically modified not to express OX2R (Knock-Out mice) and Wild-Type mice (normal mice) were investigated for psychostimulant effects when mazindol was administered.

• The study demonstrated that Knock Out mice were 70% less sensitive to mazindol than normal mice, confirming mazindol's potent activity as an OX2R agonist.

• Price Action: NLSP shares are up 0.58% at $3.39 on the last check Tuesday.

See more from Benzinga

• Click here for options trades from Benzinga

• DarioHealth Scoops Up Digital Behavioral Health Platform For M

• BTIG Sees 260% Upside In Mustang Bio With PT of ; Early-Stage MB-101 Starts Dosing Brain Tumor Patients

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.